Condition: Advanced Solid Tumors · Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.
This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS.
This description comes directly from the study's public registry record.
David S. Hong, MD · (713) 563-1930 · dshong@mdanderson.org
Always discuss trial participation with your own doctor first.
| The Lindner Center for Research & Education at The Christ Hospital | Cincinnati, Ohio, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Huntsman Cancer Institute and Hospital, University of Utah | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06096974